



UBS Speeder Plus Certificate

Linked to MSCI World Index

Issued by UBS AG, London Branch

Cash settlement

WKN: UY4E10 / ISIN: DE000UY4E100 / Valor: 47666953



Public Offer

Final Termsheet

Information on Underlying

Underlying	Strike	Cap Level	Participation Rate (PRate)	Kick-in Level	Multiplier
MSCI World Index Bloomberg: MXWO Equity Reuters: .MSCIWO	2,126.88 (100%) (Official closing price of the Underlying on the Fixing Date)	2,871.29 (135%)	1.00 (100%)	1169.78 (55%)	4.7017227 (1/Strike Level)

Product Details

Security Numbers	WKN: UY4E10 ISIN: DE000UY4E100 Valor: 47666953 Common Code: 199713663
Redemption Currency	USD
Selling Commission	Up to 1.50%
Issue Price	USD 1,000 (Units quotation)
Nominal Amount (NA)	USD 1,000

Dates

Subscription Period*	21 May 2019 – 07 June 2019 (16:00h C.E.T)
Fixing Date	07 June 2019
Issue Date	17 June 2019
Last Trading Date	03 June 2022
Expiration Date	07 June 2022
Maturity Date	14 June 2022
Banking Day	TARGET2

*In case of earlier closing or extending of the Subscription Period, the Fixing Date, the first listing date and the Payment Date may be postponed accordingly. If the Fixing Date is not an Underlying Calculation Date in relation to the Underlying or if a market disruption prevails, the immediately succeeding Underlying Calculation Date deemed to be the relevant Fixing Date .

Contact: UBS Limited
5 Broadgate, London EC2M 2QS

Equities / Risk Management Products
Marco Tuninetti (Tel: 44 207 568 4742 / 0380; Fax 44 207 568 4237)
Internet: www.ubs.com/keyinvest

Please note that calls may be recorded. Should you call one of these numbers, we shall assume that you consent to this business practice.

Redemption

The Investor is entitled to receive from the Issuer on the Maturity Date the Redemption Amount according to the following:

- a) If a Kick-in Event **has not occurred** the Investor will receive the Settlement Amount calculated in accordance with the following formula, subject to the Multiplier:

$$NA \times [\text{Strike} + \text{PRate} \times \text{MAX}(0, \text{MIN}(\text{Cap Level}, \text{Settlement Price}) - \text{Strike})]$$

- b) **If a Kick-in Event has occurred**

- a. In case the Settlement Price of the Underlying is equal or higher than the Strike, the Investor will receive the Settlement Amount calculated in accordance with the following formula, subject to the Multiplier:

$$NA \times [\text{Strike} + \text{PRate} \times (\text{MIN}(\text{Cap Level}, \text{Settlement Price}) - \text{Strike})]$$

- b. In case the Settlement Price of the Underlying is lower than the Strike, the Investor will receive the Settlement Amount calculated in accordance with the following formula:

$$NA \times \frac{\text{Settlement Price}}{\text{Strike}}$$

Settlement Price	Closing price of the Underlying on the Expiration Date.
Kick-in Event	A Kick-In Event occurs if the Closing Price of Underlying is during the Observation Period at least once lower than the Kick-In Level .
Observation Period	Expiration Date

General Information

Issuer	UBS AG, London Branch
Issuer Rating	A1 Moody's / A+ S&P's / AA- Fitch
Lead Manager	UBS Europe SE
Issue Size	10,000 Certificates
Calculation Agent	UBS AG, London Branch
Paying Agent	UBS AG, London Branch
Status	Unsecured / Unsubordinated
Listing / Secondary Market	EuroTLX
Minimum Investment	1 Certificate
Minimum Trading Lot	1 Certificate
Clearing	Euroclear, Clearstream Banking AG, Clearstream Banking S.A. (Global Note at Clearstream Banking AG)

Contact: UBS Limited
5 Broadgate, London EC2M 2QS

Equities / Risk Management Products
Marco Tuninetti (Tel: 44 207 568 4742 / 0380; Fax 44 207 568 4237)
Internet: www.ubs.com/keyinvest

Custody	Clearstream Banking AG eligible (up-to Global Note filed with Clearstream AG, Frankfurt am Main)
Public Offering	Italy
Form of Deed	Global Note
Governing Law / Jurisdiction	German / Frankfurt
Adjustments	The terms of the Product may be subject to adjustments during its lifetime. Detailed information on such adjustments is to be found in the Product Documentation.

The validity of the subscription offer by the distributor vis-à-vis the Issuer is subject to the condition that the decision of admission to trading on EuroTLX is released by EuroTLX Sim S.p.A. by not later than on the day immediately preceding the Issue Date; otherwise, the offer by the distributor will be deemed withdrawn and the issuance cancelled. The Issuer undertakes vis-à-vis the distributor to file the relevant application with EuroTLX in due time to allow EuroTLX to release a decision, according to its rules, within the Issue Date (excluded). For the avoidance of doubt: The Issuer explicitly excludes all and any liability for any direct, indirect or consequential loss arising from the rejection of the listing application.

Important Information

This information is communicated by UBS AG and/or its affiliates ("UBS"). UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the transaction to which the termsheet relates. UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this term sheet. UBS' trading and/or hedging activities related to this transaction may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier is crossed. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available.

In certain circumstances UBS sells these notes to dealers and other financial institutions at a discount to the issue price or rebates to them for their own account some proportion of the issue price. Further information is available on request.

Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in any transaction.

This document is for information purposes only and should not be construed as an offer, personal recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. The terms of any investment will be exclusively subject to the detailed provisions, including risk considerations, contained in the Information Memorandum, Prospectus or other issuer documentation for the issue of the Notes (the "Prospectus").

UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This term sheet shall not be copied or reproduced without UBS's prior written permission.

No action has been or will be taken in any jurisdiction that would permit a public offering of the securities described herein, save where explicitly stated in the Prospectus. The securities must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold.

Selling Restrictions

Contact: UBS Limited
5 Broadgate, London EC2M 2QS

Equities / Risk Management Products
Marco Tuninetti (Tel: 44 207 568 4742 / 0380; Fax 44 207 568 4237)
Internet: www.ubs.com/keyinvest

Any Products purchased by any person for resale may not be offered in any jurisdiction in circumstances which would result in the Issuer being obliged to register any further documentation relating to this Product in such jurisdiction.

The restrictions listed below must not be taken as definitive guidance as to whether this Product can be sold in a jurisdiction. Additional restrictions on offering, selling or holding of this Product may apply in other jurisdictions. Investors in this Product should seek specific advice before on-selling this Product.

Europe - Any public offer of this Product within an EEA jurisdiction (EU member states plus Norway, Iceland and Liechtenstein) shall only be possible if compliant with the requirements of the EUPD and with the law of that jurisdiction.

If the prospectus either does not qualify as a prospectus published in accordance with the requirements of the EUPD or is not filed with or notified to the relevant Financial Supervisory Authority, this Product may not be offered or sold in EEA jurisdictions other than 1) in minimum denominations of, or total consideration per investor of at least, EUR 50,000 (or equivalent in other currencies), provided that the offer is only being made in one or more EEA jurisdiction that will not, before the end of the offer period for the Securities, have implemented the provision under the Directive 2010/73/EU (the "PD Amending Directive") that increases this minimum denomination (or total consideration per investor) to EUR 100,000; or 2) only to Qualified Investors; and/or (aggregated for all distributors) to less than 100 or, if the relevant EEA jurisdiction has implemented the relevant provision of the 2010 PD Amending Directive, 150 natural or legal persons that are not Qualified Investors per EEA jurisdiction. "Qualified Investors" are persons or entities as defined in the Prospectus Directive.

For information on public offering in EEA jurisdictions please see under section "General Information" above.

Hong Kong – Each purchaser has represented and agreed that it has not issued or had in its possession for the purposes of issue, and will not issue or have in its possession for the purposes of issue, whether in Hong Kong or elsewhere, any advertisement, invitation or document relating to the Products, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to Products which are or are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance.

This is a structured product which involves derivatives. Do not invest in it unless you fully understand and are willing to assume the risks associated with it. If you are in any doubt about the risks involved in the product, you may clarify with the intermediary or seek independent professional advice.

Singapore - This document has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this document and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of this Product may not be circulated or distributed, nor may this Product be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act (Chapter 289) of Singapore (the "SFA"), (ii) to a relevant person pursuant to Section 275(1), or any person pursuant to Section 275(1A), and in accordance with the conditions specified in Section 275, of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

Where this Product is subscribed or purchased under Section 275 of the SFA by a relevant person which is:

- (a) a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or
 - (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor,
- securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the securities pursuant of an offer made under Section 275 of the SFA except:
- (1) to an institutional investor or to a relevant person defined in Section 275(2) of the SFA, or to any person arising from an offer referred to in Section 275(1A) or Section 276 (4)(i)(B) of the SFA;
 - (2) where no consideration is or will be given for the transfer;
 - (3) where the transfer is by operation of law; or
 - (4) as specified in Section 276 (7) of the SFA; or
 - (5) as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore.

Contact:

UBS Limited
5 Broadgate, London EC2M 2QS

Equities / Risk Management Products
Marco Tuninetti (Tel: 44 207 568 4742 / 0380; Fax 44 207 568 4237)
Internet: www.ubs.com/keyinvest

UK – For the purpose of non-discretionary accounts, this Product should not be sold with a consideration of less than EUR 100,000 or equivalent.

USA - This Product may not be sold or offered within the United States or to U.S. persons.

This information is communicated by UBS AG and/or its affiliates ("UBS"). UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the transaction to which the termsheet relates. UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this term sheet. UBS' trading and/or hedging activities related to this transaction may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier is crossed. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available.

In certain circumstances UBS sells these notes to dealers and other financial institutions at a discount to the issue price or rebates to them for their own account some proportion of the issue price. Further information is available on request.

Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in any transaction.

This document is for information purposes only and should not be construed as an offer, personal recommendation or solicitation to conclude a transaction and should not be treated as giving investment advice. The terms of any investment will be exclusively subject to the detailed provisions, including risk considerations, contained in the Information Memorandum, Prospectus or other issuer documentation for the issue of the Notes (the "Prospectus").

UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This term sheet shall not be copied or reproduced without UBS's prior written permission.

No action has been or will be taken in any jurisdiction that would permit a public offering of the securities described herein, save where explicitly stated in the Prospectus. The securities must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold.

Contact:

UBS Limited
5 Broadgate, London EC2M 2QS

Equities / Risk Management Products
Marco Tuninetti (Tel: 44 207 568 4742 / 0380; Fax 44 207 568 4237)
Internet: www.ubs.com/keyinvest